%dd-cfDNA: The New Frontier for Heart/Lung Transplant Surveillance?

Area of Science:

• Transplant immunology
• Biomarker discovery
• Noninvasive diagnostics

Background:

• Allograft rejection threatens long-term transplant success.
• Current surveillance methods, like biopsies, are invasive and have limitations.
• %dd-cfDNA is a promising noninvasive biomarker for allograft injury.

Purpose of the Study:

• To review the evidence for %dd-cfDNA in thoracic transplantation.
• To delineate the limitations of current %dd-cfDNA assays.
• To explore emerging cfDNA technologies for improved monitoring.

Main Methods:

• Systematic literature review of studies on %dd-cfDNA in thoracic transplant recipients.
• Analysis of performance data from centralized commercial %dd-cfDNA assays.
• Discussion of limitations and confounders reported in published studies.

Main Results:

• Published studies report heterogeneous performance of %dd-cfDNA assays.
• Significant blind spots and confounders affect current %dd-cfDNA testing.
• Emerging cfDNA methodologies offer potential for more individualized monitoring.

Conclusions:

• %dd-cfDNA shows potential as a noninvasive biomarker for thoracic allograft injury.
• Current assays have limitations requiring careful interpretation.
• Future cfDNA strategies may reduce reliance on invasive biopsies for transplant monitoring.